| 摘要 |
FIELD: chemistry.SUBSTANCE: invention relates to a novel compound of formula (I) or a pharmaceutically acceptable salt thereof, having inhibitory activity on human neutrophil elastase (HNE). In formula (I), A is C-R; Rand Rare hydrogen; Ris hydrogen; Rand Rare independently selected from hydrogen and C-C-alkyl, which can be substituted with halogen; Ris selected from -COOH, -COOR, -CONH, -CONHRand -CONRR, where Rand Rindependently represent (C-C)alkyl; -X-X- is -CR=N- or -NR-CO-; Rand R, each independently, represent a radical of formula -[Y]-[Alk]-[Alk]-Z, where Y is -(C=O)NR- or -NR(C=O)-, where Ris hydrogen or C-C-alkyl; m, p, q are independently equal to 0 or 1; provided that m, p and q are not simultaneously equal to 0, when -X-X- is -CR=N-; Alkand Alk, each independently, denote C-C-alkylene radical; Z is -N(R)(R), where Rand Rindependently represent hydrogen or C-C-alkyl group.EFFECT: compounds can be used for treating a disease or condition, which is a chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), emphysema, emphysema caused by smoking, or mucoviscidosis, asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, ulcerative colitis or irritable bowel disease.14 cl, 4 ex |
